7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Chronic Disease D002908 7 associated lipids
Cleidocranial Dysplasia D002973 1 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Coronary Disease D003327 70 associated lipids
Crohn Disease D003424 12 associated lipids
Cryptosporidiosis D003457 3 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Dengue D003715 2 associated lipids
Dental Occlusion, Traumatic D003769 1 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Theoleyre S et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. 2004 Cytokine Growth Factor Rev. pmid:15561602
Mori T et al. RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. 2004 Nucleic Acids Res. pmid:15562003
Ling JQ and Li JP [Insulin-like growth factor-II and basic fibroblast growth factor affect periodontal ligament cells expressing osteoprotegerin in vitro]. 2004 Hua Xi Kou Qiang Yi Xue Za Zhi pmid:15562643
Zhang D et al. [Expression of OPG and RANKL at protein level in human periodontal ligament cells and the effect of 1alpha,25(OH)(2) vitamin D(3) on the secretion of OPG protein in vitro]. 2004 Beijing Da Xue Xue Bao pmid:15605102
Kumamoto H and Ooya K Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. 2004 J. Oral Pathol. Med. pmid:14675140
Suda K et al. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation. 2004 J. Immunol. pmid:14764723
Brubaker KD et al. Bone morphogenetic protein signaling in prostate cancer cell lines. 2004 J. Cell. Biochem. pmid:14689587
Zhang D et al. The expression of osteoprotegerin and the receptor activator of nuclear factor kappa B ligand in human periodontal ligament cells cultured with and without 1alpha,25-dihydroxyvitamin D3. 2004 Arch. Oral Biol. pmid:14693199
Matsumoto T [Recent advances in the regulation of bone remodeling]. 2004 Nippon Rinsho pmid:15035093
Okumura S et al. [Regulatory mechanism of osteoclast differentiation and function]. 2004 Nippon Rinsho pmid:15035103
Udagawa N et al. [Possible role of RANKL in bone resorption]. 2004 Nippon Rinsho pmid:15035104
Inoue D [OPG(osteoprotegerin)/OCIF(osteoclastogenesis inhibitory factor)]. 2004 Nippon Rinsho pmid:15035105
Suzuki Y [Stimulator of bone resorption interleukin-1, interleukin-6 and gp-130 cytokine family]. 2004 Nippon Rinsho pmid:15035106
Miyaura C [LPS]. 2004 Nippon Rinsho pmid:15035108
Tanaka Y [Adhesion molecules in the context with bone remodeling and osteoporosis]. 2004 Nippon Rinsho pmid:15035110
Tomoyasu A and Higashio K [Osteoclastogenesis inhibitory factor/osteoprotegerin(OCIF/OPG)]. 2004 Nippon Rinsho pmid:15035190
Sohen S [Glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis and collagen diseases]. 2004 Nippon Rinsho pmid:15035207
Tanaka Y [Secondary osteoporosis due to systemic autoimmune diseases and rheumatic diseases]. 2004 Nippon Rinsho pmid:15035208
Fukunaga J and Sugahara T [Osteoporosis induced by immunosuppressant]. 2004 Nippon Rinsho pmid:15035219
Juji T and Tanaka S [Novel therapeutic approach to bone metabolic disorders using RANKL vaccination]. 2004 Nippon Rinsho pmid:15035230
Huang JC et al. PTH differentially regulates expression of RANKL and OPG. 2004 J. Bone Miner. Res. pmid:14969393
He J et al. Emdogain promotes osteoblast proliferation and differentiation and stimulates osteoprotegerin expression. 2004 Oral Surg Oral Med Oral Pathol Oral Radiol Endod pmid:14970783
Naumann U et al. Expression and functional activity of osteoprotegerin in human malignant gliomas. 2004 Acta Neuropathol. pmid:14504888
Saidenberg-Kermanac'h N et al. Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis. 2004 J. Clin. Immunol. pmid:15163893
Melhus H Soluble RANKL and risk of nontraumatic fracture. 2004 JAMA pmid:15187049
Pennisi P et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. 2004 Osteoporos Int pmid:14661073
Wise GE et al. Regulation of secretion of osteoprotegerin in rat dental follicle cells. 2004 Eur. J. Oral Sci. pmid:15458504
Dai SM et al. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. 2004 Ann. Rheum. Dis. pmid:15479886
Wang JC et al. Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG). 2004 Exp. Hematol. pmid:15504545
Chen Q et al. Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. 2004 Horm. Metab. Res. pmid:15523591
Saidenberg-Kermanac'h N et al. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. 2004 Bone pmid:15542046
Boabaid F et al. The role of parathyroid hormone-related protein in the regulation of osteoclastogenesis by cementoblasts. 2004 J. Periodontol. pmid:15515341
Franck H et al. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. 2004 J. Rheumatol. pmid:15517638
Ueland T Bone metabolism in relation to alterations in systemic growth hormone. 2004 Growth Horm. IGF Res. pmid:15519248
Kitaura H et al. Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo. 2004 J. Immunol. pmid:15470024
Notoya M et al. Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells. 2004 Biochem. Biophys. Res. Commun. pmid:15474477
Price PA et al. Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. 2004 J. Biol. Chem. pmid:14578360
Tian QX and Huang GY [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts]. 2004 Zhongguo Yi Xue Ke Xue Yuan Xue Bao pmid:15379268
Nitta K et al. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. 2004 Am. J. Kidney Dis. pmid:15384019
Wang L et al. Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34). 2004 J. Bone Miner. Res. pmid:15355561
Sato T et al. Interleukin-11 as an osteoprotegerin-inducing factor in culture medium of blastic cells from a patient with acute megakaryocytic leukemia complicated with osteosclerosis. 2004 Am. J. Hematol. pmid:15307108
Giuliani N et al. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). 2004 Exp. Hematol. pmid:15308315
Colucci S et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. 2004 Blood pmid:15308561
Miyazaki T et al. Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats. 2004 J. Cell. Biochem. pmid:15372622
Jeffcoate W Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link? 2004 Diabetologia pmid:15322748
Liu Z et al. Production of recombinant human osteoprotegrin from Trichoplusia ni cells and Bombyx mori larvae. 2004 Protein Pept. Lett. pmid:15327363
Politou M et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). 2004 Br. J. Haematol. pmid:15327520
Erdogan B et al. Intima-media thickness of the carotid arteries is related to serum osteoprotegerin levels in healthy postmenopausal women. 2004 Neurol. Res. pmid:15327755
Hofbauer LC and Schoppet M Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. 2004 JAMA pmid:15280347
Kanatani M et al. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. 2004 J. Cell. Physiol. pmid:15281085
Xiao XH et al. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro]. 2004 Zhonghua Yi Xue Za Zhi pmid:15730627
Matsuo K and Ray N Osteoclasts, mononuclear phagocytes, and c-Fos: new insight into osteoimmunology. 2004 Keio J Med pmid:15247511
Tiranathanagul S et al. Actinobacillus actinomycetemcomitans lipopolysaccharide activates matrix metalloproteinase-2 and increases receptor activator of nuclear factor-kappaB ligand expression in human periodontal ligament cells. 2004 J. Periodontol. pmid:15732867
Mosheimer BA et al. Expression and function of RANK in human monocyte chemotaxis. 2004 Arthritis Rheum. pmid:15248232
Xu D et al. Development of a chimaeric receptor approach to study signalling by tumour necrosis factor receptor family members. 2004 Biochem. J. pmid:15250821
De Leenheer E et al. Evidence of a role for RANKL in the development of myeloma bone disease. 2004 Curr Opin Pharmacol pmid:15251126
Kazama JJ Osteoprotegerin and bone mineral metabolism in renal failure. 2004 Curr. Opin. Nephrol. Hypertens. pmid:15199291
Walsh NC and Gravallese EM Bone loss in inflammatory arthritis: mechanisms and treatment strategies. 2004 Curr Opin Rheumatol pmid:15201606
Terpos E et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. 2004 Leukemia pmid:15215875
Brändström H et al. A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). 2004 Blood Press. pmid:15223723
Wilson SE et al. RANK, RANKL, OPG, and M-CSF expression in stromal cells during corneal wound healing. 2004 Invest. Ophthalmol. Vis. Sci. pmid:15223796
Pioletti DP and Kottelat A The influence of wear particles in the expression of osteoclastogenesis factors by osteoblasts. 2004 Biomaterials pmid:15172492
Livshits G et al. Genetic influences on the circulating cytokines involved in osteoclastogenesis. 2004 J. Med. Genet. pmid:15173242
De Wilde A et al. A low dose of daidzein acts as an ERbeta-selective agonist in trabecular osteoblasts of young female piglets. 2004 J. Cell. Physiol. pmid:15174095
Ueland T et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. 2004 J. Am. Coll. Cardiol. pmid:15542278
Taranta A et al. Imbalance of osteoclastogenesis-regulating factors in patients with celiac disease. 2004 J. Bone Miner. Res. pmid:15176994
Demer LL and Abedin M Skeleton key to vascular disease. 2004 J. Am. Coll. Cardiol. pmid:15542279
Coetzee M and Kruger MC Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment? 2004 South. Med. J. pmid:15180028
Vidal K et al. Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. 2004 Am. J. Physiol. Gastrointest. Liver Physiol. pmid:15521102
Abedin M et al. Vascular calcification: mechanisms and clinical ramifications. 2004 Arterioscler. Thromb. Vasc. Biol. pmid:15155384
Vidal K et al. Osteoprotegerin in human milk: a potential role in the regulation of bone metabolism and immune development. 2004 Pediatr. Res. pmid:15155868
Xiao HL et al. Expression and identification of mutated osteoprotegerin in culture cells and larvae of silkworm. 2004 Acta Biochim. Biophys. Sin. (Shanghai) pmid:15156274
Lee CK et al. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. 2004 Arthritis Rheum. pmid:15593184
Grzegorzewska AE and MÅ‚ot M Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease. 2004 Rocz. Akad. Med. Bialymst. pmid:15631341
Grzegorzewska AE and MÅ‚ot M Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. 2004 Rocz. Akad. Med. Bialymst. pmid:15631342
Naumnik W et al. Serum levels of osteoprotegerin (OPG) and pro gastrin releasing peptide (ProGRP) during chemotherapy of lung cancer. 2004 Rocz. Akad. Med. Bialymst. pmid:15638385
Franchimont N et al. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. 2004 Clin. Exp. Immunol. pmid:15544627
Eaton CL et al. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. 2004 Prostate pmid:15042606
O' Gradaigh D et al. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. 2004 Ann. Rheum. Dis. pmid:15020327
Ichinose Y et al. Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading. 2004 Calcif. Tissue Int. pmid:15549649
Collantes Estévez E and González Domínguez J [Bone Paget's disease in the young adult]. 2004 Rev Clin Esp pmid:15456600
Collin-Osdoby P Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. 2004 Circ. Res. pmid:15564564
Sato N et al. MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha. 2004 J. Exp. Med. pmid:15353553
Neville-Webbe HL et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. 2004 Breast Cancer Res. Treat. pmid:15567943
Mizutani Y et al. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. 2004 Cancer pmid:15386310
Miao D et al. Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. 2004 Endocrinology pmid:15090463
Haynes DR et al. Regulation of osteoclast activity in peri-implant tissues. 2004 Biomaterials pmid:15109848
Ito S and Hata T Crystal structure of RANK ligand involved in bone metabolism. 2004 Vitam. Horm. pmid:15110169
Hao C et al. Modulation of TRAIL signaling complex. 2004 Vitam. Horm. pmid:15110173
Kiechl S et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. 2004 Circulation pmid:15117849
Pritzker LB et al. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. 2004 Mol. Biol. Cell pmid:15064358
Salmon P Loss of chaotic trabecular structure in OPG-deficient juvenile Paget's disease patients indicates a chaogenic role for OPG in nonlinear pattern formation of trabecular bone. 2004 J. Bone Miner. Res. pmid:15068491
Morabito N et al. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. 2004 J. Bone Miner. Res. pmid:15068494
Durán A et al. The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. 2004 Dev. Cell pmid:14960283
Wang FS et al. Nitric oxide donor increases osteoprotegerin production and osteoclastogenesis inhibitory activity in bone marrow stromal cells from ovariectomized rats. 2004 Endocrinology pmid:14962990
Harashima SI et al. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand expression in fibroblast-like synoviocytes from rheumatoid arthritis and osteoarthritis patients. 2004 Rheumatology (Oxford) pmid:14963213
Hofbauer LC et al. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. 2004 Clin. Endocrinol. (Oxf) pmid:14725683
Altun A et al. Decreased serum osteoprotegerin levels in patients with cardiac syndrome X. 2004 J. Endocrinol. Invest. pmid:15648548
Kanzaki H et al. Local OPG gene transfer to periodontal tissue inhibits orthodontic tooth movement. 2004 J. Dent. Res. pmid:15557398
Zhang X et al. Synovial fibroblasts infected with Salmonella enterica serovar Typhimurium mediate osteoclast differentiation and activation. 2004 Infect. Immun. pmid:15557643

Table of Content